Brief: Apimeds Pharmaceuticals US Enters Assignment And Transfer Agreement With Freet On August 19
21/08/2026 22:31
BRIEF-Apimeds Pharmaceuticals US Enters Assignment And Transfer Agreement With Freet On August 19 Aug 21 (Reuters) - Apimeds Pharmaceuticals US Inc APUS.A:
APIMEDS PHARMACEUTICALS US - ENTERS ASSIGNMENT AND TRANSFER AGREEMENT WITH FREET ON AUG 19, 2026 - SEC FILING
APIMEDS PHARMACEUTICALS US - FREET ASSIGNS ALL APITOX-RELATED RIGHTS TO APIMEDS PHARMACEUTICALS - SEC FILING
APIMEDS PHARMACEUTICALS US - RECEIVES 100% KOREAN CLINIC RIGHTS, 25% U.S. ROYALTY, 25% OVERSEAS REVENUE PARTICIPATION FOR APITOX - SEC FILING
APIMEDS PHARMACEUTICALS US - ASSIGNED RIGHTS ARE FREE AND CLEAR OF PRIOR CLAIMS OR ENCUMBRANCES - SEC FILING
Source text: [ID:n0001213900-26-092680]
Further company coverage: APUS.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Apimeds Pharmaceuticals US
See all newsBrief: Mindwave Innovations Signs 3 Client Network Agreements In 10 Days, Extending Mindchain Into Climate Finance, Sports Media And Insurance Apimeds Pharmaceuticals Us Provides Required NYSE American Disclosure
Brief: Apimeds Pharmaceuticals US Enters Assignment And Transfer Agreement With Freet On August 19
Brief: Apimeds Pharmaceuticals Us Inc Vin Menon Continues To Serve As The Company’S Chief Executive Officer
Brief: Apimeds Pharmaceuticals Appoints Youngjik Cho As Chairman Of Board
Brief: Apimeds Pharmaceuticals Us Inc. Announces Material Breach Of Merger Agreement By Inscobee Inc And Apimeds Inc